Regentis Biomaterials Ltd

Research Regentis Biomaterials Ltd (RGNT) on Bullrun: market cap USD 19.53M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRGNT
• ExchangeNYSE MKT
• CountryIsrael
• SectorHealthcare
• IndustryMedical Instruments & Supplies
• CurrencyUSD
• Market capUSD 19.53M
• Financial periodFY2025
• Net income-USD 13.65M

Valuation Snapshot

latest market cap is USD 19.53M.

About Regentis Biomaterials Ltd

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.

Frequently asked questions

What is Regentis Biomaterials Ltd's market cap?

Regentis Biomaterials Ltd's market capitalization is USD 19.53M.

What does Regentis Biomaterials Ltd do?

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States.